Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6890-6899
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6890
Table 1 Demographic data in the two groups

EA (n = 57)
DPE (n = 58)
Z/t/χ2
95%CI of difference
P value
Age (yr)28.0 (26.0-30.0)28.0 (25.0-30.0)0.766-1.0, 1.00.4432
Height (cm)159.7 ± 3.8160.6 ± 4.21.159-2.4, 0.60.2491
Weight (kg)73.0 (69.5-75.0)73.5 (71.8-76.0)1.622-3.3, 0.20.1052
BMI (kg/m2)28.2 ± 1.928.5 ± 1.70.981-1.0, 0.30.3292
Gestational age (w)39.8 ± 1.139.5 ± 1.11.450-0.1, 0.70.1501
Hb (g/l)116.7 ± 8.5117.0 ± 8.30.223-3.5, 2.80.8241
HCT (%)35.4 ± 2.335.0 ± 2.20.782-0.5, 1.20.4361
ASA physical status
Class 16 (10.5)10 (17.2)1.0820.1, 1.70.2983
Class 251 (89.5)48 (82.8)
Table 2 Details of anesthesia, adverse effects, and neonatal outcomes

EA (n = 57)
DPE (n = 58)
Z/t/χ2
95%CI of difference
P value
The onset time to T6 level (min)16.6 (15.8-17.4)14.7 (13.9-15.4)4.039-5.0, 0.00.0012
Maximum sensory level (T)5 (4-6)5 (4-5)1.1200.0, 1.00.2632
Modified bromage score to 3, n (%)21 (36.8)45 (77.6)19.5162.6, 13.5< 0.001
Cranial sensory block to T6, n (%)30 (52.6)54 (93.1)23.9153.8, 38.0< 0.001
Vasopressor administration, n (%)6 (10.5)9 (15.5)0.6310.5, 4.70.4273
Intraoperative IV analgesic supplementation, n (%)16 (28.1)7 (12.1)4.6000.1, 0.90.0323
Local anesthetic volume (ml)20.0 (17.5-20.0)20.0 (15.0-20.0)0.4290.0, 0.00.6682
Fluid administration (ml)800.0 (750.0-800.0)800.0 (700.0-800.0)0.8060.0, 0.00.4242
Estimated blood loss (ml)400.0 (400.0-400.0)400.0 (300.0-400.0)1.5480.0, 0.00.1222
Duration of surgery (min)37.4 ± 8.336.3 ± 6.30.746-3.7, 1.70.4571
Urine output (ml)100.0 (100.0-150.0)100.0 (100.0-150.0)0.2480.0, 0.00.8042
Adverse effects, n (%)
Hypotension5 (8.8)2 (3.5)1.4250.1, 2.00.4223
Respiratory depression0 (0.0)0 (0.0)0.0000.0, 0.01.0003
Postdural headache0 (0.0)0 (0.0)0.0000.0, 0.01.0003
Nausea and vomiting7 (12.3)5 (8.6)0.4120.2, 2.30.5213
Chest distress5 (8.8)7 (12.1)0.3340.4, 4.80.5633
Dizzy6 (10.5)4 (6.9)0.4770.2, 2.40.7193
Nasal obstruction5 (8.8)6 (10.3)0.0820.3, 4.20.7743
Chills19 (33.3)14 (24.1)1.1880.3, 1.40.2763
Neonatal outcomes
Apgar score < 8 at 1 min, n (%)3 (5.3)2 (3.4)0.0000.1, 4.00.9843
Apgar score < 8 at 5 min, n (%)0 (0.0)0 (0.0)0.0000.0, 0.01.000
Table 3 Sensory nerve and motor block levels in the two groups at each time point after drug injection

Group
5 min
10 min
15 min
20 min
5 min after operation
Sensory block levels of cranial sideEA (n = 57)T11 (T10-11)T9 (T7-T9)T6 (T5-T7)T5 (T4-T6)T5 (T5-T6)
DPE (n = 58)T10 (T10-11)T8 (T7-T8)T6 (T5-T6)T5 (T4-T6)T5 (T4-T6)
95%CI0.349-1.0200.064-0.9050.381-1.1410.262-0.4360.078-0.705
P value< 0.0010.024< 0.0010.6230.115
Ptime < 0.001, Pgroup = 0.008, Pinteraction < 0.001
Sensory block levels of sacral sideEA (n = 57)L1 (L1-L3)L3 (L2.5-L4)L5 (L4-S1)S1 (S1-S1)S1 (S1-S1)
DPE (n = 58)L2 (L2-L2.3)L4 (L3-L4)S1 (L5-S1)S1 (S1-S2)S1 (S1-S2)
95%CI0.471-0.9660.245-0.9920.319-0.9250.078-0.7100.269-0.734
P value< 0.0010.001< 0.0010.015< 0.001
Ptime < 0.001, Pgroup < 0.001, Pinteraction = 0.425
Motor block scoreEA (n = 57)0.0 (0.0-0.0)1.0 (0.0-1.0)1.0 (1.0-2.0)2.0 (1.0-3.0)3.0 (2.0-3.0)
DPE (n = 58)1.0 (1.0-1.0)1.0 (1.0-2.0)2.5 (2.0-3.0)3.0 (3.0-3.0)3.0 (3.0-3.0)
95%CI0.443-0.7570.631-1.1530.773-1.3540.507-1.0080.210-0.636
P value< 0.001< 0.001< 0.001< 0.001< 0.001
Ptime < 0.001, Pgroup < 0.001, Pinteraction < 0.0011